Featured Story | By Nick Paul Taylor Pfizer has revealed the new home of its TYK2 inhibitors. Months after disclosing a pact with a mystery startup, the Big Pharma has taken the wrapping off a deal with Priovant Therapeutics, a new Roivant unit that will seek to bring brepocitinib to market in dermatomyositis and lupus. read more |
| |
|---|
|
Top Stories By Max Bayer As regulators and elected officials consider reforming the accelerated approval process, BIO chairman Paul Hastings is mounting a vigorous defense against proposals he says could threaten innovation. read more By Nick Paul Taylor Astellas has struck its second immuno-oncology deal of the month. The latest pact will see the Japanese drugmaker pay Sutro Biopharma $90 million, plus potentially upward of $1 billion in biobucks, for rights to three immunostimulatory antibody-drug conjugates, a modality designed to combine the best features of ADCs and personalized vaccine biology. read more By James Waldron Kezar’s hopes for zetomipzomib to become a catch-all drug for inflammatory disease having been stunted earlier in the year, new phase 2 data suggest the therapy is still in play to treat lupus nephritis. read more By Gareth Macdonald Regulators' efforts to boost trial diversity are not enough, according to Phesi, which says data from unrepresentative studies should not be considered good quality. The artificial intelligence technology firm made the comments this week to coincide with a new analysis of clinical studies conducted over the past 15 years. read more By Gabrielle Masson To help crack Alzheimer's disease, researchers are looking to a North Star—or, more accurately, a star-shaped cell in the brain that could play a role in progression of the neurodegenerative disease. read more By Annalee Armstrong A small data set but big improvement in the hearing loss brought on by chemotherapy was enough to send Decibel Therapeutics' shares soaring in premarket trading Tuesday. read more By Dave Muoio Single- and multistate provider organizations alike may find it difficult to keep their women's health services within the bounds of the law, attorneys say. read more By Nick Paul Taylor DermBiont’s bet on SeylanMED has delivered a win in phase 2. Twenty months after acquiring the topical drug candidate SM-020, DermBiont has linked the prospect to improved outcomes in people with benign tumors, causing the phase 2 clinical trial to meet its primary and secondary endpoints. read more By Andrea Park After rocketing to medtech stardom amid the COVID-19 pandemic, Cue Health seems to be drifting back down to Earth. read more By Robert King CMS announced a new payment model aimed at improving care coordination and services for cancer treatments, including a new focus on improving health equity. read more By Kevin Dunleavy Jazz Pharmaceuticals has revealed a setback, saying that its nabiximols oromucosal spray has flunked a phase 3 trial, coming up short in helping multiple sclerosis patients with lower-limb spasticity. Over a 21-day span, the spray—known as Sativex and on the market in Europe for 12 years—failed to improve muscle tone as measured by the Modified Ashworth Scale (MAS). read more Resources Sponsored By: Blue Matter Consulting For an emerging biopharma company, Europe can be very attractive. But it can also be complex and confusing. This e-book covers the 12 most common pitfalls for companies entering European markets for the first time, offering guidance to help growing companies avoid them and succeed. Sponsored By: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Blue Matter, strategic consultants in the life sciences Medical Affairs plays a critical role in generating insights to inform strategic decisions, but that role is changing. This paper explores why, and how MA teams can stay ahead of the curve. Sponsored By: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: PwC Don’t miss these critical considerations when evaluating your HCP interactions management program. Sponsored By: Thermo Fisher Scientific Sponsored by Thermo Fisher Scientific The journey for starting or expanding a lab can be exhilarating, while also being challenging--learn how this free program provides savings and solutions to support your goals. Sponsored by: CG Life Explore the new cell therapy handbook from Thermo Fisher Scientific. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? | 
